» Articles » PMID: 29268106

Food Components with Antifibrotic Activity and Implications in Prevention of Liver Disease

Overview
Journal J Nutr Biochem
Date 2017 Dec 22
PMID 29268106
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing prevalence of nonalcoholic fatty liver disease (NAFLD) in parallel with the obesity epidemic has been a major public health concern. NAFLD is the most common chronic liver disease in the United States, ranging from fatty liver to steatohepatitis, fibrosis and cirrhosis in the liver. In response to chronic liver injury, fibrogenesis in the liver occurs as a protective response; however, prolonged and dysregulated fibrogenesis can lead to liver fibrosis, which can further progress to cirrhosis and eventually hepatocellular carcinoma. Interplay of hepatocytes, macrophages and hepatic stellate cells (HSCs) in the hepatic inflammatory and oxidative milieu is critical for the development of NAFLD. In particular, HSCs play a major role in the production of extracellular matrix proteins. Studies have demonstrated that bioactive food components and natural products, including astaxanthin, curcumin, blueberry, silymarin, coffee, vitamin C, vitamin E, vitamin D, resveratrol, quercetin and epigallocatechin-3-gallate, have antifibrotic effects in the liver. This review summarizes current knowledge of the mechanistic insight into the antifibrotic actions of the aforementioned bioactive food components.

Citing Articles

Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders.

Cheng M, Ding F, Li L, Dai C, Sun X, Xu J Front Pharmacol. 2025; 16:1517174.

PMID: 39950117 PMC: 11822302. DOI: 10.3389/fphar.2025.1517174.


Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?.

Sokal-Dembowska A, Jarmakiewicz-Czaja S, Ferenc K, Filip R Int J Mol Sci. 2024; 25(10).

PMID: 38791276 PMC: 11120776. DOI: 10.3390/ijms25105238.


Does Resveratrol Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)?.

Kasprzak-Drozd K, Nizinski P, Kasprzak P, Kondracka A, Oniszczuk T, Rusinek A Int J Mol Sci. 2024; 25(7).

PMID: 38612556 PMC: 11012111. DOI: 10.3390/ijms25073746.


Pterostilbene: a potential therapeutic agent for fibrotic diseases.

Wang W, Li K, Bai D, Wu J, Xiao W Inflammopharmacology. 2024; 32(2):975-989.

PMID: 38429613 DOI: 10.1007/s10787-024-01440-z.


Association between frailty and hepatic fibrosis in NAFLD among middle-aged and older adults: results from NHANES 2017-2020.

Atabieke F, Li X, Aierken A, Li J, Zhang Y, Aizezi Y Front Public Health. 2024; 12:1330221.

PMID: 38389936 PMC: 10883311. DOI: 10.3389/fpubh.2024.1330221.


References
1.
Oliveira K, Buss C, Tovo C . Association of caffeine intake and liver fibrosis in patients with chronic hepatitis C. Arq Gastroenterol. 2015; 52(1):4-8. DOI: 10.1590/S0004-28032015000100002. View

2.
Brunt E, W-S Wong V, Nobili V, Day C, Sookoian S, Maher J . Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2016; 1:15080. DOI: 10.1038/nrdp.2015.80. View

3.
Cabrera C, Artacho R, Gimenez R . Beneficial effects of green tea--a review. J Am Coll Nutr. 2006; 25(2):79-99. DOI: 10.1080/07315724.2006.10719518. View

4.
Kim B, Farruggia C, Ku C, Pham T, Yang Y, Bae M . Astaxanthin inhibits inflammation and fibrosis in the liver and adipose tissue of mouse models of diet-induced obesity and nonalcoholic steatohepatitis. J Nutr Biochem. 2017; 43:27-35. DOI: 10.1016/j.jnutbio.2016.01.006. View

5.
Schelter F, Halbgewachs B, Baumler P, Neu C, Gorlach A, Schrotzlmair F . Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1α. Clin Exp Metastasis. 2010; 28(2):91-9. DOI: 10.1007/s10585-010-9360-x. View